Health: Flu Vaccine Research

Baroness Knight of Collingtree Excerpts

Wednesday 23rd November 2011 Lords Chamber

Asked By

[Baroness Knight of Collingtree]

To ask Her Majesty’s Government whether they propose to fund research into more effective flu vaccines, in the light of the recent report in The Lancet.

[Earl Howe]

My Lords, research on the development of new flu vaccines is being actively carried out by academic departments in universities, biotechnology companies and vaccine manufacturers. There are number of improved vaccines in the final stages of development and licensed products may become available over the next few years. The department does not fund the development of new vaccines, but does support some work on basic research and research to inform policy in this area.

[Baroness Knight of Collingtree]

My Lords, did the Lancet report not warn that the currently used vaccine is effective for only six out of 10 of the persons receiving it, and that the virus can actually change to outwit that vaccine? Has my noble friend studied a more recent report from the chief virologist at Barts and the Royal Hospital about a new vaccine which not only gives lifelong protection in only one jab but also overrides the virus changes? Would it not be a real boon for patients if this were looked at more carefully, and perhaps brought in? It would save a lot of money for the NHS.

[Earl Howe]

My noble friend is extremely well informed. I have not seen the report that she mentioned. The only licensed vaccines currently supplied to the UK are inactivated trivalent influenza vaccines, but it is expected that within the next few years others will become available, including a live attenuated trivalent intranasal vaccine next year. In the future, an adjuvanted vaccine and a quadrivalent vaccine may also become available. The JCVI—the Joint Committee on Vaccination and Immunisation—has looked at some of these new vaccines and believes that they present exciting prospects for greater efficacy.